Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial

8 de junio de 2026 actualizado por: Zhongshan Ophthalmic Center, Sun Yat-sen University
This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

142

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Qi Fu
  • Número de teléfono: 86+66619334
  • Correo electrónico: fuqi@gzzoc.com

Ubicaciones de estudio

    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510060
        • Zhongshan Ophthalmology Center, Sun Yat sen University
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Voluntarily participate and sign an informed consent form;
  2. Age range: 18 to 60 years old;
  3. Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;
  4. 1/3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;
  5. The best corrected visual acuity for each eye is ≥ 0.5;
  6. Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;
  7. Women with reproductive potential agree to use reliable contraceptive methods during the study period;
  8. Willing and able to complete all planned research visits and follow the guidance of the researchers.

Exclusion Criteria:

  1. Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);
  2. Had undergone corneal refractive surgery (e.g., LASIK/SMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;
  3. Participation in other medical studies within 3 months prior to enrollment screening;
  4. Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).

    Meningitis, choroiditis, uveitis, scleritis, etc.;

  5. Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);
  6. Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);
  7. Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;
  8. Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;
  9. Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;
  10. During pregnancy or lactation;
  11. Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);
  12. Uncontrolled ocular or systemic diseases;
  13. History of epilepsy;
  14. The investigator determines that the subject is not suitable for participation in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: glass rod group
Implement glass rod assisted eyelid massage for a total of 4 times
The participants of control group receive sodium hyaluronate eye drops 4 times a day for 8 weeks, and receive glass rod assisted eyelid massage based on the group standard of "Meibomian gland massage operation procedure" (T/GDPMAA003-2023) every 2 weeks, for a total of 4 times. Follow up evaluations will be conducted at weeks 4 and 8
Experimental: eyelid support plate group
Implement eyelid support plate assisted eyelid massage for a total of 4 times.
The participants of experimental group receive sodium hyaluronate eye drops in both eyes four times a day for 8 weeks, and receive eyelid support plate assisted eyelid massage based on the group standard of Meibomian gland massage procedure (T/GDPMAA003-2023) every two weeks for a total of four times. Follow up evaluations will be conducted at weeks 4 and 8.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean change from baseline in Ocular Surface Disease Index (OSDI) score at week 8
Periodo de tiempo: Baseline, week 4, week 8
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
Baseline, week 4, week 8

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in first non-invasive tear film break time
Periodo de tiempo: Baseline, week 4, week 8
The time (in seconds) from the blink that evenly distributed the fluorescein to the appearance of the first tear breakup was recorded. First non-invasive tear film rupture time (NIBUTf) was measured using an ocular surface analyzer (Keratography 5M, Oculus, Germany),
Baseline, week 4, week 8
proportion of Ocular Surface Disease Index (OSDI) scores showing a change ≥10 points from baseline at week 8
Periodo de tiempo: Baseline, week 4, week 8
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
Baseline, week 4, week 8

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Average operating time of eyelid massage (min)
Periodo de tiempo: Baseline, week 2, week 4, week 6
Record the operating time of each eyelid massage treatment in two groups (after completing surface anesthesia, from the start of eyelid massage to the completion of squeezing the upper and lower eyelids of both eyes, each eyelid is squeezed twice), timed by the same timer, and after the timer is over, the operating time (min) is recorded after verification by two researchers.
Baseline, week 2, week 4, week 6
change in non-invasive lacrimal height measurement(NITMH)
Periodo de tiempo: Baseline, week 4, week 8
Non-invasive lacrimal height measurement(NITMH)(mm) using an ocular surface analyzer (Keratography 5M, Oculus, Germany)
Baseline, week 4, week 8
Change in meibomian gland absence status
Periodo de tiempo: Baseline, week 4, week 8
Measurement of meibomian gland deficiency using an ocular surface analyzer (Keratography 5M, Oculus, Germany). Grading criteria for meibomian gland deficiency: 0 points (normal)=no meibomian gland deficiency, 1 point (mild)=meibomian gland deficiency ratio less than 1/3, 2 points (moderate)=meibomian gland deficiency ratio between 1/3 and 2/3, 3 points (severe)=meibomian gland deficiency ratio greater than 2/3. Determine the extent and severity of meibomian gland deficiency, calculate the sum of upper and lower eyelid grading scores for each eye, with a total score range of 0-6 points.
Baseline, week 4, week 8
Change in lipid layer thickness (LLT)
Periodo de tiempo: Baseline, week 4, week 8
Evaluation of lipid layer yhickness (LLT)(nm) using LipiView
Baseline, week 4, week 8
Change in partial blink frequency
Periodo de tiempo: Baseline, week 4, week 8
Evaluation of partial blink frequency (%) using LipiView.
Baseline, week 4, week 8
Changes in Meibomian gland discharge ability score
Periodo de tiempo: Baseline, week 4, week 8
Apply force to the eyeball within the range of 5 meibomian gland openings outside and in the center of the lower eyelid eyelash line, and observe the number of meibomian gland openings that can discharge meibomian gland secretions. Grading criteria: 0 points (normal)=all 5 meibomian gland openings excrete secretions, 1 point (mild)=3 or 4 meibomian gland openings excrete secretions, 2 points (moderate)=1 or 2 meibomian gland openings excrete secretions, 3 points (severe)=no meibomian gland openings excrete secretions,The higher the score, the worse the discharge ability.
Baseline, week 4, week 8
Change in score of meibomian gland secretions
Periodo de tiempo: Baseline, week 4, week 8
Scoring by operator based on secretion characteristics. Grading criteria:0 points (normal)=clear and transparent liquid secretion,1 point (mild)=cloudy liquid secretion,2 points (moderate)=cloudy granular secretion,3 points (severe)=thick and toothpaste like secretion.The higher the score, the worse the quality of the secretion
Baseline, week 4, week 8
comfort scores for four sessions of eyelid massage in two groups
Periodo de tiempo: Baseline, week 2, week 4, week 6
Use the Visual Analog Scale (VAS) to score the comfort of the operation.The scale is mainly composed of a 100mm straight line, with one end representing "completely painless" and the other end representing "the most severe pain imaginable" or "extreme pain". The score range is from 0 to 100, where 0 represents complete painlessness and 100 represents the most severe pain experienced by the patient. Patients will be asked to mark the corresponding position on this line (using an "X") to represent the intensity of pain they experienced at that time. Within 1 minute after each operation, have participants mark the corresponding position on the scale to indicate the intensity of their pain at that time, and promptly record each result.
Baseline, week 2, week 4, week 6

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2026

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de junio de 2026

Publicado por primera vez (Actual)

8 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de junio de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2026KYPJ065

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir